Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).
Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly. In the US more than 350 product labels include new pediatric information and more than 130 products have undergone a pediatric focused post-labelling safety review. In Europe there has been 221 changes regarding the safety and efficacy of medicines from the submission of old or new studies in children and 89 additions of dosing information for children as a direct consequence of Paediatric Investigation Plans (PIPs).
Request a Free Sample Copy of this Report @ http://www.radiantinsights.com/research/pediatric-drug-development-regulatory-challenges-and-commercial-opportunities/request-sample
Despite the apparent success of the pediatric regulation, the submission of pediatric information is complex and the incentives are often insufficient to encourage industry innovation (Rose & Della Pasqua, 2011). No new drugs can be registered in the EU without a detailed PIP being approved by the EMA’s Pediatric Committee (PDCO) (Rose, 2014). Without a PIP, the registration process for a new drug can be blocked. In the US, the FDA has adopted a more pragmatic approach to pediatric drug development, providing voluntary and mandatory routes for pediatric evaluation.
Many experts agree that there is significant room to improve the EU pediatric regulations and a revision of the legislation is scheduled to take place in 2018. In the meantime, there is considerable potential for the industry to develop pediatric formulations and doses of approved and generic medicines, particularly for use in transition countries where access to high quality pediatric formulation is improving. In addition, new commercial opportunities exist to develop medicines that target pediatric specific conditions in neonates as well as rare and neglected diseases and pediatric vaccines.
– Pediatric medicines: an overview
– The pediatric population
– Underlying/key issues for pediatric drug development
– Unmet clinical needs
– Current landscape
– Regulation and legislation
– Global harmonization
– Strategic considerations for developing pediatric medicines
– Clinical trial considerations
– Pediatric formulation issues
– Pediatric networks
– Patient access
– Commercial opportunities
– Generic formulations and dosage forms
– Rare and neglected diseases
– Pediatric vaccines
Down load full research of Report @ http://www.radiantinsights.com/research/pediatric-drug-development-regulatory-challenges-and-commercial-opportunities
Key Reasons to Purchase
– Reviews the current regulatory landscape and helps sponsors to understand the potential impact of FDA SIA regulations and the variations between EU regulation on global pediatric plans;
– Identifies the key challenges associated with pediatric drug development and the ways to overcome these hurdles;
– Assesses what issues need to be addressed in order to improve access to pediatric medicines and commercial opportunities in transition countries based on KOL insights;
– Analyses different strategies to develop age-appropriate medicines in niche therapeutic fields in neonates, rare and neglected pediatric diseases and pediatric vaccines.
Browse all Report of this category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email : firstname.lastname@example.org
visit our website : http://www.radiantinsights.com/
Phone: (415) 349-0054
Address: 28 2nd Street, Suite 3036
City: San Francisco
Country: United States